Sequencing Throughout Multiple Lines of Therapy in RR DTC
Before closing out their discussion on RR DTC management, panelists consider the advent of sequencing through multiple lines of therapy.
Optimizing Use of RET Inhibitors in Patients With RR DTC
Shared insight on the optimal use of RET inhibitor therapy in select patients with RET-rearranged radioiodine-refractory differentiated thyroid cancer.
Patient Scenario 3: Treating RR DTC With an Identified RET Fusion
Centering discussion on the final clinical scenario of RR DTC, Francis Worden, MD, highlights the management of a patient with an identified RET rearrangement.
Practical Considerations for Utilizing Second-Line Therapy in RR DTC
Expert panelists provide comprehensive insight to the utilization of second-line therapy for patients with RR DTC, covering formulation, dosing, and adverse event management.
Clinical Data Behind Second-Line Therapy in RR DTC
A broad view of clinical data behind use of cabozantinib therapy in the second-line setting of radioiodine-refractory differentiated thyroid cancer.
Patient Scenario 2: Second-Line Management of RR DTC With Cabozantinib
Moving on to a new clinical scenario, Lori Wirth, MD, reviews the second-line management of a patient who progresses on frontline systemic therapy.
RR DTC: Managing Adverse Events With Dose Reductions or Holds
Before closing out their discussion on the frontline treatment setting of RR DTC, panelists highlight dose reductions and planned treatment holidays to mitigate adverse events.
Quality of Life and Real-World Data in Patients With RR DTC
Expert perspectives on real world and quality of life data behind systemic therapy in patients with radioiodine-refractory differentiated thyroid cancer.
Overview of Available Treatment Options for RR DTC
Expert oncologists work together to review the treatment armamentarium for radioiodine-refractory differentiated thyroid cancer and identify factors that best inform selection of therapy.
RR DTC: Active Surveillance vs Initiating Systemic Therapy
A brief review of when it is appropriate to initiate systemic therapy in patients with differentiated thyroid cancer as opposed to continuing active surveillance.
Defining Radioiodine-Refractory Differentiated Thyroid Cancer
Key opinion leaders in differentiated thyroid cancer take a moment to define radioiodine refractory disease and consider its implications in establishing a treatment pathway.
Practical Considerations for Managing RR DTC With Systemic Therapy
Comprehensive insight on best practices in dose adjustment and adverse event management in patients receiving systemic therapy for RR DTC.
Patient Scenario 1: RR DTC Managed With Frontline Lenvatinib
Expert Marcia Brose, MD, PhD, reviews a patient case of radioiodine-refractory differentiated thyroid cancer (RR DTC) managed with frontline lenvatinib therapy.
Real-World Treatment Patterns and Clinical Outcomes in Radioiodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC) Patients Treated with Lenvatinib Monotherapy
Dr Worden reviews and discusses real-world data of lenvatinib monotherapy in patients with radioiodine-refractory differentiated thyroid cancer.
Continued ADC Development in NSCLC Necessitates Improved Knowledge of Mechanisms and Biomarker Optimization
Neoadjuvant vs Perioperative Immune Checkpoint Blockade in Resectable NSCLC: How Do We Choose?
EGFR TKI–Based Combinations May Revolutionize Frontline EGFR+ NSCLC Management
Dr Olazagasti on a Case-Based Discussion of ALK-Mutated NSCLC Treatment
2 Commerce Drive Cranbury, NJ 08512